Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve-Calming amino acid may cut heart risk in kidney disease

NCT ID NCT03982160

Knowledge-focused Sponsor: The University of Texas at Arlington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether a single infusion of L-arginine, an amino acid, can reduce abnormally high sympathetic nerve activity in people with chronic kidney disease (CKD). High nerve activity is linked to increased cardiovascular risk in CKD patients. Researchers will measure nerve signals in the leg before and after the infusion to see if L-arginine helps lower this activity. The study involves 15 adults aged 35 to 75 with moderate CKD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
L-Arginine
What this could lead to
If successful, this could point toward a new way to lower cardiovascular risk in chronic kidney disease patients by calming an overactive nervous system.
What could go wrong
This is a small, early-phase study with only 15 participants, so results may not apply to all patients. The intervention is a single infusion, not a long-term treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2018

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race. * Men and women 35 to 75 years of age Exclusion Criteria: * myocardial infarction * heart failure * anemia (hemoglobin \<8 g/dl) * cancer with current treatment * previous organ transplantation * immunosuppressant therapy * human immunodeficiency virus infection * pregnancy and/or lactating * current tobacco use * taking menopausal drugs (estradiol) * treatment for diabetic neuropathy * resting heart rate ≥ 100 bpm and * systolic blood pressure ≤ 90 mmHg

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

Contacts and locations

Locations

  • UT Southwestern

    Dallas, Texas, 75390, United States

  • University of Delaware

    Newark, Delaware, 19716, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.